Head-to-head evidence
Albuterol Sulfate (Provenetil-HFA) vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Albuterol Sulfate (Provenetil-HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
Proventil-HFA serves here as the active reference product against which the investigational albuterol-HFA is compared in a secondary analysis, while the trial's main comparison is between the investigational product and placebo; no results have been posted yet.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
Vilanterol
Marketed by GlaxoSmithKline
NCT01706198 · Phase 3 · completed
The study randomized 4,233 participants to FF/VI or active usual care, but neither participants nor investigators were blinded. Its primary patient-reported asthma-control endpoint was a surrogate/soft measure and was met in favor of FF/VI (71% vs 56%; p<0.001), supporting moderate rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuterol Sulfate (Provenetil-HFA)'s landscape · Vilanterol's landscape